AU2004227852B2 - Zwitterionic immunomodulators for the treatment of asthma and allergy - Google Patents

Zwitterionic immunomodulators for the treatment of asthma and allergy Download PDF

Info

Publication number
AU2004227852B2
AU2004227852B2 AU2004227852A AU2004227852A AU2004227852B2 AU 2004227852 B2 AU2004227852 B2 AU 2004227852B2 AU 2004227852 A AU2004227852 A AU 2004227852A AU 2004227852 A AU2004227852 A AU 2004227852A AU 2004227852 B2 AU2004227852 B2 AU 2004227852B2
Authority
AU
Australia
Prior art keywords
polymer
cells
subject
asthma
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004227852A
Other languages
English (en)
Other versions
AU2004227852A1 (en
Inventor
Dennis L. Kasper
Arthur O. Tzianabos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2004227852A1 publication Critical patent/AU2004227852A1/en
Application granted granted Critical
Publication of AU2004227852B2 publication Critical patent/AU2004227852B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2004227852A 2003-03-31 2004-03-31 Zwitterionic immunomodulators for the treatment of asthma and allergy Ceased AU2004227852B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45905603P 2003-03-31 2003-03-31
US60/459,056 2003-03-31
PCT/US2004/009838 WO2004089407A2 (en) 2003-03-31 2004-03-31 Zwitterionic immunomodulators for the treatment of asthma and allergy

Publications (2)

Publication Number Publication Date
AU2004227852A1 AU2004227852A1 (en) 2004-10-21
AU2004227852B2 true AU2004227852B2 (en) 2010-01-14

Family

ID=33159613

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004227852A Ceased AU2004227852B2 (en) 2003-03-31 2004-03-31 Zwitterionic immunomodulators for the treatment of asthma and allergy

Country Status (6)

Country Link
US (4) US20040219160A1 (https=)
EP (1) EP1638581A2 (https=)
JP (1) JP2006522135A (https=)
AU (1) AU2004227852B2 (https=)
CA (1) CA2520865A1 (https=)
WO (1) WO2004089407A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CA2479246C (en) * 2002-03-13 2017-05-09 Laurie E. Comstock Method for overexpression of zwitterionic polysaccharides
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
CA2620416A1 (en) * 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics S.R.L. Zwitterionization of capsular saccharides
US8206726B2 (en) * 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
JP2008255084A (ja) * 2007-04-04 2008-10-23 Isako Hashimoto 抗花粉症剤または食品
JP2011503104A (ja) * 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
US20110002965A1 (en) * 2007-11-09 2011-01-06 Round June L Immunomodulating compounds and related compositions and methods
EP2252326A4 (en) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd VACCINE COMPOSITIONS
US20100275282A1 (en) * 2009-04-23 2010-10-28 Round June L Methods and systems for identifying immunomodulatory substances
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2011006029A1 (en) 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
JP2013530949A (ja) * 2010-05-20 2013-08-01 エル ラウンド ジューン 抗原特異的Ｔｒｅｇ並びに関連する組成物、方法及びシステム
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
US20140248289A1 (en) * 2011-08-26 2014-09-04 University Of Cincinnati Methods and Compositions for the Treatment of Respiratory Conditions Via NKG2D Inhibition
US9057070B2 (en) 2011-10-03 2015-06-16 California Institute Of Technology Generation of Bacteriodes fragilis capsular polysaccharide A-only producing mutant strain
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
CA2911826C (en) 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
US10765696B2 (en) * 2015-06-10 2020-09-08 City Of Hope Compositions of and methods of treatment with zwitterionic polysaccharide
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
RU2018124307A (ru) 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN109481474A (zh) * 2017-09-11 2019-03-19 广州知易生物科技有限公司 脆弱拟杆菌在制备防治鼻炎的药物或食品中的应用
US20210033610A1 (en) * 2018-02-12 2021-02-04 The Research Foundation For The State University Of New York Intracellular nitric oxide as a biomarker for increased susceptibility systemic inflammation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56128721A (en) * 1980-03-12 1981-10-08 Eisai Co Ltd Antiallergic agent
US4835252A (en) * 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
WO2003075953A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
EP1358885A1 (en) * 2001-01-12 2003-11-05 Amato Pharmaceutical Products, Ltd. Antiallergic agents
EP1459757A1 (en) * 1999-04-02 2004-09-22 The Brigham And Women's Hospital, Inc. Immunomodulating polymers

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2001A (en) * 1841-03-12 Sawmill
US2888741A (en) * 1955-03-22 1959-06-02 American Metallurg Products Co Alloys
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
SE456346B (sv) * 1984-07-23 1988-09-26 Pharmacia Ab Gel for att forhindra adhesion mellan kroppsvevnader och sett for dess framstellning
US4619995A (en) * 1984-12-24 1986-10-28 Nova Chem Limited N,O-carboxymethyl chitosan and preparative method therefor
EP0229829B1 (en) * 1985-07-12 1995-02-22 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
US4684727A (en) * 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
US4819617A (en) * 1986-09-04 1989-04-11 University Of Florida Viscoelastic material for ophthalmic surgery
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
DE3704389A1 (de) 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung von lymphokinen durch induktion lymphoider zellen
US5215896A (en) * 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US4937270A (en) * 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5140016A (en) * 1988-05-31 1992-08-18 University Of Florida Method and composition for preventing surgical adhesions using a dilute solution of polymer
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
HU9201966D0 (en) * 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5130417A (en) * 1990-04-30 1992-07-14 Washington University Entamoeba histolytical immunogenic protein and cdna clone
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
GB2254083A (en) 1991-03-28 1992-09-30 Italfarmaco Spa Anticoagulants from e.coli saccharide
GR920100122A (el) * 1991-04-05 1993-03-16 Ethicon Inc Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
EP0667787B1 (en) * 1992-09-24 2001-07-18 Brigham And Women's Hospital Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
EP0740708B1 (en) * 1993-11-26 2004-08-04 Lawrence B. Hendry Design of drugs involving receptor-ligand-dna interactions
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
CA2204355C (en) * 1994-11-02 2001-01-16 Gail Mandel Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5679658A (en) 1995-05-08 1997-10-21 Chitogenics, Inc. N,O-carbonxymethylchitosan for prevention of surgical adhesions
DK0971961T3 (da) 1997-04-04 2003-03-24 Fidia Advanced Biopolymers Srl N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
WO1999048524A1 (en) * 1998-03-03 1999-09-30 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
DE69920198T2 (de) * 1998-04-13 2005-09-22 Massachusetts Institute Of Technology, Cambridge Kamm-polymere zur regelung der zelloberflächenwechselwirkung
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
CN1362880A (zh) * 1999-04-02 2002-08-07 布赖汉姆妇女医院 免疫调制聚合物
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
JP2001055335A (ja) * 1999-08-18 2001-02-27 Toshio Sato アレルギー性皮膚疾患治療剤
US6995237B1 (en) * 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CA2479246C (en) * 2002-03-13 2017-05-09 Laurie E. Comstock Method for overexpression of zwitterionic polysaccharides
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2006115066A1 (ja) * 2005-04-21 2006-11-02 Toray Industries, Inc. パンツ
US8206726B2 (en) * 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
JP2011503104A (ja) * 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56128721A (en) * 1980-03-12 1981-10-08 Eisai Co Ltd Antiallergic agent
US4835252A (en) * 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
EP1459757A1 (en) * 1999-04-02 2004-09-22 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
EP1358885A1 (en) * 2001-01-12 2003-11-05 Amato Pharmaceutical Products, Ltd. Antiallergic agents
WO2003075953A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kalka-Moll W M et al: J. Immunology, vol. 164, no. 2, 15 Jan 2000, pages 719-724 *
Pat Abs Japan vol. 060, no. 003 , 9 Jan 1982 & JP 56128721 A, 8 Oct 1981 *
TZIANABOS A O et al: J. Biol Chem, Am Soc Biol Chemists, vol. 275, no. 10, 10/3/2000, pp 6733-40 *

Also Published As

Publication number Publication date
US20040219160A1 (en) 2004-11-04
US20140099331A1 (en) 2014-04-10
WO2004089407A3 (en) 2005-01-20
US20110059125A1 (en) 2011-03-10
WO2004089407A2 (en) 2004-10-21
EP1638581A2 (en) 2006-03-29
CA2520865A1 (en) 2004-10-21
AU2004227852A1 (en) 2004-10-21
JP2006522135A (ja) 2006-09-28
US20120315264A1 (en) 2012-12-13
US9265790B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
US9265790B2 (en) Zwitterionic immunomodulators for the treatment of asthma and allergy
US10946082B2 (en) Immunomodulatory compositions and methods of use thereof
EP3341017B1 (en) Immunomodulatory compositions comprising caulobacter crescentus and use thereof
US20100310470A1 (en) Immunomodulatory polymeric antigens for treating inflammatory pathologies
US9603917B2 (en) Immunologically active compositions
US8129518B2 (en) Synthetic polysaccharide antigens for immunological intervention in disease
Flannigan Characterization of adjuvant properties of microparticulate beta-glucan
HK1227730B (en) Immunomodulatory compositions and methods of use thereof
HK1227730A1 (en) Immunomodulatory compositions and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired